Phase I-II clinical trials have assessed the toxicity and efficacy of glucose transport inhibitors, such as WZB117, fisetin, phloretin, and silybin/silibinin, for advanced HCC and prostate cancer; however, these therapies have limitations due to side effects, such as hyperbilirubinemia and elevation of alanine aminotransferase (ALT)434,435. The gene discussed is GPT; the disease is prostate carcinoma.